GCTK icon

GlucoTrack

0.4899 USD
-0.0270
5.22%
At close Feb 14, 4:00 PM EST
After hours
0.4936
+0.0037
0.76%
1 day
-5.22%
5 days
-20.93%
1 month
-79.92%
3 months
-92.06%
6 months
-98.50%
Year to date
-92.29%
1 year
-97.87%
5 years
-99.87%
10 years
-99.87%
 

About: GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

Employees: 6

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

133% more funds holding

Funds holding: 3 [Q2] → 7 (+4) [Q3]

120% more capital invested

Capital invested by funds: $60.2K [Q2] → $133K (+$72.5K) [Q3]

0.46% more ownership

Funds ownership: 0.55% [Q2] → 1.0% (+0.46%) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Research analyst outlook

We haven’t received any recent analyst ratings for GCTK.

Financial journalist opinion

Based on 4 articles about GCTK published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions.
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Neutral
GlobeNewsWire
1 week ago
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
The study met its primary endpoint with no procedure or device related serious adverse events reported The study met its primary endpoint with no procedure or device related serious adverse events reported
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
Neutral
GlobeNewsWire
2 weeks ago
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Neutral
GlobeNewsWire
3 weeks ago
Glucotrack Announces ISO 13485:2016 Certification
ISO Certification highlights commitment to quality for continuous blood glucose monitor ISO Certification highlights commitment to quality for continuous blood glucose monitor
Glucotrack Announces ISO 13485:2016 Certification
Neutral
GlobeNewsWire
1 month ago
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
Neutral
GlobeNewsWire
1 month ago
Glucotrack to Present at TechBio Showcase™ 2025
Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes
Glucotrack to Present at TechBio Showcase™ 2025
Neutral
GlobeNewsWire
2 months ago
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Feasibility study underway for the Company's novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Neutral
GlobeNewsWire
3 months ago
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a “best efforts” public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) share of common stock at an exercise price of $1.81 per share. The combined offering price of each share of common stock together with the accompanying series A and series B common warrants is $1.39, and the combined offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $1.389. The gross proceeds of the public offering were approximately $10 million before deducting placement agent fees and offering expenses.
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
Neutral
GlobeNewsWire
3 months ago
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024. Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings.
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
Neutral
GlobeNewsWire
4 months ago
GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference
GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
Charts implemented using Lightweight Charts™